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INTRODUCTION 
Nanotechnology has large potential benefits to a wide range of 
disciplines, such as environment, human health and medicine. 
Nanoparticles (NPs) are defined as particles with at least one 
dimension less than 100 nm. NPs have been designed and made as 
part of the recent advances in nanotechnology. 
NPs are emitted into the environment by primary sources such as 
natural phenomena, combustion processes or industrial activities 
(e.g. welding) or are released during generation and handling of 
engineered NPs. Because the lung is considered by far the most 
important portal of entry for NPs into the human body, this overview 
will mainly focus on the lung as a potential barrier for inhaled NPs. 
The deposition of particles in the lung is size dependent. 90% of 
inhaled 1 nm particles are deposited in the nasopharyngeal region, 
only 10% in the trachea-bronchial region, and essentially none in the 
alveolar region. 5 nm particles show about equal deposition of 
approximately 30% of the inhaled particles in all three regions. 20 
nm particles have the highest deposition efficiency in the alveolar 
region (~ 50%), whereas in trachea-bronchial and nasopharyngeal 
regions this particle size deposits with approximately 15% efficiency. 
Deposited NPs overcome the tissue barrier as well as the cellular 
membranes and translocate to extrapulmonary sites and reach other 
target organs by transcytosis across epithelia of the respiratory tract 
into the interstitium and access to the blood circulation directly or via 
lymphatics, resulting in distribution throughout the body. They reach 
first the central compartment of the body, and finally the central 
nervous system after damaging and penetrating the blood brain 
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barrier. The toxicokinetics of NPs has not been elucidated yet, and 
the most of evidence is based on animal models. 
 
Investigations of metal and metal oxide NPs are currently an area of 
intense scientific research, due to a wide variety of potential 
applications in medical diagnostics, cosmetics industry, optical and 
electronic fields. Iron oxide nanoparticles (IONPs) with their unique 
magnetic properties have a high potential for use in several 
biomedical applications, including magnetic drug targeting, magnetic 
detection, hyperthermia and magnetic resonance imaging. 
Toxicological examination of NPs is essential before we can fully 
exploit their advantages in practical applications and ensure that 
potential adverse consequences are minimized. 
IONPs are found naturally in the environment as particulate matter in 
air pollution and in volcanic eruptions. Either magnetite or 
maghemite – the two most commonly studied iron oxides − particles 
can be generated as emissions from traffic, industry and power 
stations but can also be specifically synthesised chemically for a 
wide variety of applications (so-called engineered nanoparticles). 
 
The aim of this study was determination the potential, and up to now 
not completely examined, adverse effects associated with iron oxide 
NPs following airways exposure, including general and specific 
toxicological actions (on the respiratory system, immune system and 
on certain macromolecules). Both in vivo animal tests and in vitro 
examinations have notable advantages and disadvantages; but by 
combining these in a complex experimental model, early detection of 
possible toxicological effects can be achieved, and new relationships 
 5 
 
between the primary outcomes can be revealed. This thesis 
comprises both in vivo and in vitro tests for toxicological 
examination of iron oxide NPs. We looked for answers to the 
following questions: 
 
• Does intratracheal application of iron oxide nanoparticles 
cause any general toxic effect and general and or specific 
histopathological changes in rat organs? 
 
• Does it cause any specific toxic effect on rat respiratory 
system?  
o Does it change production of any immunoglobulin in 
the early stage of exposure in BAL and the whole 
blood?  
o Does it cause changes of some components of 
pulmonary redox system? 
 
• Does it cause any harmful effect in in vitro cell lines?  
o Does it cause any damage in the primary culture of rat 
lung cells and human A549 cell line?  
o If yes, is there any relationship between cell damage 
and production of pro-inflammatory proteins?  
o Does it induce cytotoxic effect in another mammalian 
cell line? 
 
• Can mutagenic activity be detected in bacterial cells exposed 
to iron oxide nanoparticles? 
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METHODS 
In in vivo experiments male rats were treated once intratracheally 
with 1 and/or 5 mg/ml iron oxide nanoparticles. The instilled volume 
was 1 ml/kg body weight. An untreated control (UnC, neither 
anesthesia nor intratracheal instillation) and a vehicle control group 
(Con, anesthetized and vehicle treated) was used. In Experiment I 
each group contained 30 animals at start and 6 of the 30 rats per 
group were sacrificed after 1, 3, 7, 14 and 30 days, respectively. In 
Experiment II each group contained 24 animals at start and 6 of the 
24 rats per group were sacrificed after 1, 3, 7 and 14 days. In 
Experiment III each group contained 12 animals at start and 6 of the 
12 rats per group were sacrificed after 7 and 30 days, respectively. 
In Experiment I, body and organ weights (brain, liver, lungs, heart, 
kidneys, spleen, thymus and adrenals) were monitored, and 
histopathological analysis was undertaken. 
In Experiment II, immunological studies were performed. Blood 
samples were taken from the abdominal aorta and bronchoalveolar 
lavage (BAL) was carried out with physiological saline. IgA, IgG, 
and IgM concentrations were determined by the sandwich ELISA 
(enzyme-linked immunosorbent) assay. 
In Experiment III, effect of iron oxide NPs on pulmonary redox 
system were examined. The treated animals’ lungs were frozen in 
liquid nitrogen and placed in a freezer. On the day of examination, 
after homogenisation of the lungs, samples were centrifuged. Total 
gluthatione (GSH) estimation was determined using the GSH 
reductase method. Extracellular Cu,Zn/superoxide dismutase (EC-
SOD) was estimated with the use of a Randox kit. 
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In in vitro studies effect of iron oxide NPs on primary culture of rat 
lung cells (alveolar macrophages and type II pneumocytes isolated 
from male rats) and human A549 cell line, and potential relationship 
between cell damage and proinflammatory proteins was assessed. 
Finally, cytotoxic and genotoxic effects of these nanoparticles were 
studied on Mammalian Vero cell line and bacterial strains, 
respectively. 
In Experiment IV, animal alveolar macrophages, type II 
pneumocytes and human A549 lung cells were examined by lectin 
histochemistry assay (for detection of oligosaccharide molecules 
bound to protein molecules in the cell membranes) and chemokines 
levels were measured. Lung cells were exposed to iron oxide NPs at 
doses 1, 5, and 10 µg/ml. 
In Experiment V potential relationship between cell damage and 
production of chemokines were examined. The primary culture of rat 
lung cells were exposed to iron oxide NPs at doses 1, 5, and 
10 µg/ml. After 24 h incubation the supernatants of the cells were 
collected and sandwich ELISA was used to measure chemokines 
(MCP-1 and MIP-1α) levels. 
In Experiment VI, Vero cells were grown in 96-well plates (3000 
cells/well) until subconfluent. IONPs were then added to the cells at 
78, 156, 313, 625, 1250, 2500, 5000 and 10000 μg/ml concentration, 
and incubated for 4 and 24 hours. Percentage viability of the cells was 
calculated as the ratio of mean absorbance of triplicate readings of 
sample wells (Isample) compared to the mean absorbance of control wells 
(Icontrol): Cell viability (%) = (Isample/Icontrol) × 100. 
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In Experiment VII, Ames test was used for assess the genotoxic 
potential of chemicals and pharmaceuticals. The test employs 
histidine dependent mutant (Salmonella typhimurium) and 
tryptophan dependent (Escherichia colii) strains.  
 
All values were expressed as Mean±S.D. From the general 
toxicological data, group means (±SD) were calculated. All data 
were tested for significance with one-way analysis of variance 
(ANOVA), and significant difference between the groups was tested 
using a two-way paired Student’s t-test, the MTT analyses were 
performed using Student’s t-test for unpaired data. P values < 0.05 
were considered statistically significant. The results of 
immunoglobulins were calculated on the basis of Bazin’s results. 
Ames test data were processed using standard statistical software 
COLONY with recommendation of UKEMS (U.K. Environmental 
Mutagen Society). 
RESULTS 
Intratracheal instillation of iron oxide NPs caused a significantly 
slowed body weight gain compared to the control groups. Among the 
relative organ weights, weight of the lungs decreased significantly 
with increasing dose and time. Histopathological examination 
revealed no abnormalities in the exposed rats’ organs (lungs, liver, 
kidneys and spleen) except in the lungs, where the interstitium was 
widened and a weak pulmonary fibrosis developed by the end of 
examination period. 
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Immunological examination showed that 1 mg/ml iron oxide NPs 
decreased the IgA level in the blood but not in BAL. IgG and IgM 
(immunoglobulins of peripherial airways) showed significant 
decrease in BAL whereas they did not alter in the blood. 
In biochemical examination GSH and EC-SOD were estimated. At 7 
and 30 days after the exposure by IONPs neither GSH content nor EC-
SOD activity could be measured. 
 
According to in vitro lectin histochemistry assay at lower 
concentrations, the membranes of alveolar macrophages and type II 
pneumocytes proved to be intact similarly to control, while A549 
cells showed incomplete membranes already at 1 µg/ml 
concentration. At 10 µg/ml concentration the membranes of both 
animal and human lung cells became irregular and lost continuity, 
finally the cells were fragmented. 
Iron oxide nanoparticles significantly increased the expression of 
MCP-1 and MIP-1α in AM. In PII cells, production of MCP-1 
significantly increased while MIP-1α significantly decreased. 
In cytotoxicity assay, cell viability changed from ca. 100% to 
approximately 13% with increasing iron oxide NP concentrations. 
In Ames test, the average number of revertant colonies and change in 
the background growth were similar in the nanoparticle-treated 
groups and the negative control. None of the revertant rates was 
greater than or equal to the twofold of the negative controls, and no 
concentration-dependent increase was observed. 
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EXPERIMENT AIM METHOD RESULT 
I 
general toxic effect:  
body and organ weight 
analyses 
single intratracheal 
instillation 1, 5 mg/ml 
IONPs 
significantly slowed 
body weight gain; 
weight of the lungs 
decreased 
histopathological 
examination:  
lungs, liver, kidneys, spleen 
HE, Berlin blue, 
Giemsa, Gömöri's and 
van Gieson stains 
no abnormalities in the 
exposed rats' organs 
except in the lungs 
II 
immunological examination: 
Ig level changes 
single intratracheal 
instillation 1 mg/ml 
IONPs; blood and 
broncho-alveolar 
lavage (BAL) samples 
IgA (blood): ↓ 
IgA (BAL): − 
IgG (blood): −  
IgG (BAL): ↓ 
IgM (blood): − 
IgM (BAL): ↓ 
III 
biochemical examination: 
effect of IONPs on pulmonary 
redox sytem 
single intratracheal 
instillation 1 mg/ml 
IONPs; 
homogenisated lungs 
GSH and EC-SOD 
changes: − 
Table 1 summarizes the in vivo experiments iron oxide nanoparticles (IONPs) toxicology with focus on 
aims, methods and results. 
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EXPERIMENT AIM METHOD RESULT 
IV 
effect of IONPs on primary 
culture of rat lung cells and 
human A549 cell line 
AM, PII and A549 
cells: exposition to 1-
10µg/ml IONPs (24h) 
lectin histochemistry 
assay 
IONPs caused the 
injury of cell 
membranes; human 
cells were more 
sensitive 
V 
relationship between  
cell damage and 
proinflammatory proteins 
AM, PII and A549 
cells: exposition to 1-
10µg/ml IONPs (24h) 
chemokine detection 
AM cells - MCP-1: ↑; 
AM cells - MIP-1α : ↑ 
PII cells - MCP-1: ↑; 
PII cells - MIP-1a: −  
VI 
cytotoxic effect of IONPs Vero cells: exposition 
to 78 - 10000 μg/ml 
IONPs (4 and 24h) 
time- and 
concentration 
dependent cytotoxicity 
VII 
genotoxic effect of IONPs Ames test with S. 
typhimurium and E. 
coli strains  
6.9 - 5000 μg/ml 
IONPs 
no mutagenic effect 
Table 2 summarizes the in vitro experiments iron oxide nanoparticles (IONPs) toxicology with focus on 
aims, methods and results. 
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CONCLUSION 
In conclusion, the results of this work and the questions pointed out 
as aims of the study can be answered as follows:  
 
• Acute intratracheal application of iron oxide nanoparticles 
had evident general toxic effect (altered body and lung 
weights) and caused morphological changes in the treated 
rats’ lungs.  
 
• Nanoparticles which reached the lower airways proved to be 
immunosuppressive: there was decreased immunoglobulin 
level (IgM and IgG) in the peripherial bronchioles. However, 
two components of pulmonary redox system (GSH and EC-
SOD) did not change, therefore further examination is 
required. 
 
• The nanoparticles caused irreversible injury to the 
membranes of alveolar cells. Human A549 cells were more 
sensitive than animal cells. Our results showed connection 
between damage of lung cells and production of chemokines 
(significantly elevated MCP-1 and MIP-1α levels were 
measured from the supernatant of treated lung cells). The 
alveolar epithelial cells could produce chemokines through 
which they may regulate inflammatory and immune 
responses in the alveolar microenvironment. The iron oxide 
NPs had moderate cytotoxic effect on Vero cell line.  
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• No mutagenic activity could be observed in the bacterial 
reverse mutation (Ames) test. 
 
• The new, complex experimental model, comprising both in 
vivo and in vitro investigations, proved to be suitable for early 
detection of (previously unknown or partially documented) 
toxic effects of iron oxide NPs, and for revealing certain 
connections between the individual toxic effects.  
 
From the research presented in this study, the need for more 
toxicological examination on nanoparticles is clear. In addition to 
animal experiments, there is a need to develop and use better and 
rapid screening tests. In vitro studies are likely to provide initial data 
on nanoparticles, with the findings having to be followed up by in 
vivo studies in animal. 
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